Merck & Co., Inc. $MRK Stock: Eurizon Capital SGR S.p.A. Decreases Stake

Eurizon Capital SGR S.p.A. reduced its stake in Merck & Co., Inc. by 7.3% in the third quarter, selling 174,489 shares but still holding over 2.22 million shares valued at approximately $325 million. Merck recently surpassed quarterly earnings and revenue expectations, reporting $2.49 per share and $18.09 billion in revenue, marking a 4.7% year-over-year increase. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $155.74, bolstered by positive MASH trial results that have increased optimism for Merck's drug pipeline.